NVRO Stock Recent News
NVRO LATEST HEADLINES
NEWTOWN, Pa., April 10, 2025 (GLOBE NEWSWIRE) -- Edelson Lechtzin LLP, a national class action law firm, is investigating claims regarding data privacy violations at Nevro Corp. (“Nevro”).
NEW YORK CITY, NY / ACCESS Newswire / April 10, 2025 / Nevro Corp.,recently disclosed that it suffered a data breach that compromised the sensitive personal and protected health data of individuals. This data breach has led to concerns over the security of sensitive personal and protected health information entrusted to Nevro.
NEW YORK, NY / ACCESS Newswire / April 9, 2025 / Nevro Corp., recently disclosed that it suffered a data breach that compromised the sensitive personal and protected health data of individuals.This data breach has led to concerns over the security of sensitive personal and protected health information entrusted to Nevro. WHAT'S THIS ABOUT?
NEW YORK CITY, NY / ACCESS Newswire / April 8, 2025 / Nevro Corp., recently disclosed that it suffered a data breach that compromised the sensitive personal and protected health data of individuals. This data breach has led to concerns over the security of sensitive personal and protected health information entrusted to Nevro.
OKLAHOMA CITY, April 03, 2025 (GLOBE NEWSWIRE) -- Nevro Corp. investigated by Federman & Sherwood for data breach. On April 3, 2025, Nevro Corp. filed notice of a data breach with the Attorney General of Texas.
Nevro (NVRO) reported earnings 30 days ago. What's next for the stock?
AUDUBON, Pa., April 03, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced the completion of its previously disclosed acquisition of Nevro Corp., a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain.
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Nevro Corp. (NYSE: NVRO) to Globus Medical, Inc. (NYSE: GMED). Under the terms of the proposed transaction, shareholders of Nevro will receive $5.85 in cash for each share of Nevro that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or w.
NVRO continues to gain due to its business expansion into the SI joint fusion market and optimistic 2024 results amid a weak SCS market.
NVRO's fourth-quarter earnings surpass the Zacks Consensus Estimate, while worldwide revenues decline year over year. The company continues to incur losses at the operating level.